Efficacy and Tolerability of Pantovigar® Vegan in Female Subjects With Diffuse Hair Loss

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05943860

Enrollment

Registered

2023-07-13

Start date

2021-09-13

Completion date

2022-05-31

Last updated

2023-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diffuse Hair Loss in Females

Brief summary

The objective of this study is to assess the hair growth efficacy of a Food for Special Medicinal Purposes (FSMP) Pantovigar® vegan after 3 and 6 months of intake.

Interventions

DIETARY_SUPPLEMENTPantovigar® vegan

Oral application of 1 capsule three times a day (morning, noon, evening) for 6 months

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Intervention model description

Intra-individual comparison

Eligibility

Sex/Gender

FEMALE

Age

30 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Diffuse hair loss * Modified Savin Score I to III * Hair length of at least 2 cm

Exclusion criteria

* Pathological hair loss (like alopecia areata, universalis or totalis; scarring alopecias; androgenic alopecia; inflammatory conditions of the scalp) * Symptomatic diffuse alopecia due to pathological low iron concentration or thyroid gland disorder * Acute telogen effluvium * Recent or concomitant treatment with any drugs that may cause hair loss * Concomitant diseases that can cause hair loss

Design outcomes

Primary

Measure	Time frame
Self-assessment questionnaire for product acceptance by subjects	Months 3

Secondary

Measure	Time frame
Change from baseline of blood parameters: Ferritin	Baseline up to month 6
Change from baseline of several blood parameters: Vitamin B1	Baseline up to month 6
Change from baseline of several blood parameters: Biotin	Baseline up to month 6
Effect on hair growth assessed by phototrichogram analysis	Baseline up to month 6
Change from baseline of several blood parameters: Hematocrit	Baseline up to month 6
Change from baseline of several blood parameters: Pantothenic Acid	Baseline up to months 6
Occurrence of treatment-emergent adverse reactions and treatment-emergent serious adverse reactions	Baseline up to months 6
Change from baseline of several blood parameters: Folic acid	Baseline up to month 6

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026